GLYR1

Across TCGA pan-cancer cohorts, GLYR1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GLYR1 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GLYR1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GLYR1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where GLYR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.929	0.697	.001	40	view →
UCEC	OS	Median	III,IV	0.296	1.000	<.001	34	view →
LUAD	OS	Median	All	0.862	0.601	.002	27	view →
GBM	DFS	Quartile	All	0.478	0.257	.002	7	view →
HNSC	DFS	Quartile	II,III,IV	0.468	0.793	.006	6	view →
LSCC	DFS	Tertile	All	0.810	0.590	.036	5	view →
CCRCC	DFS	Median	All	0.737	0.872	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GLYR1–PDAC (DFS)

Open the PDAC breakdown →